ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 926

Development of an Ultrasound Joint Inflammation Score for Rheumatoid Arthritis through a Data-Driven Approach

Anna-Birgitte Aga1, Elisabeth Lie2, Inge C Olsen2, Hilde Berner Hammer3, Till Uhlig4, Désirée van der Heijde5,6, Tore K. Kvien2, Espen A. Haavardsholm2 and the ARCTIC study group, 1Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, 4Diakonhjemmet Hospital, Oslo, Norway, 5Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, 6Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Disease Activity, rheumatoid arthritis (RA) and ultrasonography

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Imaging of Rheumatic Diseases I: Ultrasound

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:
No consensus exists regarding which joints and
tendons should be systematically assessed by ultrasonography (US) to assess
inflammation in rheumatoid arthritis (RA). Validity and responsiveness must be
weighted against feasibility. Our group has previously developed and validated a
US joint inflammation score (Aga et al, Ann Rheum Dis 2015). The objective of
this study was to optimize the score in terms of sensitivity to change and
feasibility, and to perform comparative analyses versus formerly proposed US
scores in a longitudinal study.

Methods: DMARD-naïve
early RA patients (pts) with <2 yrs symptom duration fulfilling the 2010
ACR/EULAR classification criteria were recruited between Sept 2010 and April
2013 and started on methotrexate. Extensive US examination were performed by
experienced sonographers at baseline (BL) and after 3 and 6 months, using a
validated grey-scale (GSUS) and power Doppler (PDUS) semi-quantitative scoring
system with scores 0-3 for GSUS and PDUS in each of the following 36 joints and
4 tendons: MCP1-5, PIP2-3, radiocarpal, distal radioulnar, intercarpal, elbow,
knee, talocrural, MTP1-5, extensor carpi ulnaris and tibialis posterior (TP)
tendons, bilaterally. An US atlas was used as reference (Hammer et al, Ann
Rheum Dis 2011). We performed principal component factor analyses (PCA) of GSUS
and PDUS changes from BL to 3 months (ΔGSUS and ΔPDUS) to identify
joint groups with high internal correlation. Based on these analyses we identified
several joints/tendons candidate sets to be further tested. Standardised
response means (SRMs) with 95% CI (bootstrapping) were estimated at 3 and 6
months for the candidate sets and formerly proposed scores.

Results: 117 early RA pts were included; 81.2% anti-CCP pos, mean(SD) age 50.3
(13.3) yrs, median(IQR) disease duration (from onset of swollen joint) 5 (3-9)
months, mean(95% CI) 36-joint GSUS score 23(21-25) and PDUS score 11(10-12). Based
on the PCA 12 groups of joint/tendons were identified (Table 1). Elbow,
TP-tendon and MTP1 came out as separate factors, but were omitted from the
scores due to low SRMs. Table 2 shows the 3- and 6-month SRMs for the previously
published candidate sets (A, B), one of the new candidate sets (C) and the
formerly proposed scores.

Conclusion: We used a data-driven approach to further develop an ultrasound
joint inflammation score in RA. We propose a novel candidate set of
joints/tendons with improved sensitivity to change, which is feasible, and performed
numerically better than formerly proposed scores. Our results show that a reduced
US assessment may efficiently contribute to disease assessment in RA.

 

Table 1: Joint/tendon groups identified by principal component factor analyses of ΔGSUS and ΔPDUS scores after 3 months with methotrexate treatment in early RA

 Group

1

Group 2

Group 3

Group 4

Group 5

Group 6

Group 7

Group 8

Group 9

Group 10

Group 11

Group 12

Radiocarpal*

Intercarpal

DRUJ

MCP3*

MCP4

MCP5

MTP2*

Elbow

MCP2*

MCP1*

MTP3*

MTP4

MTP5

TP-t

ECU-t*

PIP2*

PIP3*

MTP1

DRUJ = distal radioulnar joint; MTP = metatarsophalangeal; MCP = metacarpophalangeal; PIP = proximal interphalangeal joints; TP-t = tibialis posterior tendon; ECU-t = extensor carpi ulnaris tendon. *Joints/tendon included in the new candidate set C

 

Table 2: 3- and 6- month standardised response means (SRMs) for candidate set A, B, C and formerly proposed ultrasound joint scores for RA

 

   GSUS

SRM*(95%CI) 3 months

SRM*(95%CI) 6 months

   12-joint score Naredo¹

– 1.01 ( – 1.17 to – 0.84)

– 0.92 ( – 1.08 to – 0.76)

   7-joint score Backhaus²

– 1.10 ( – 1.30 to – 0.90)

– 1.15 ( – 1.36 to – 0.94)

   6-joint score Perricone3

– 0.99 ( – 1.19 to – 0.78)

– 0.97 ( – 1.15 to – 0.79)

   Candidate set A score⁴

– 1.04 ( – 1.23 to – 0.84)

– 1.06 ( – 1.29 to – 0.84)

   Candidate set B score⁵

– 1.06 ( – 1.27 to – 0.87)

– 1.14 ( – 1.35 to – 0.94)

   Candidate set C score⁶

– 1.25 ( – 1.48 to – 1.02)

– 1.25 ( – 1.47 to – 1.02)

 

   PDUS

SRM*(95%CI) 3 months

SRM*(95%CI) 6 months

   12-joint score Naredo¹

– 0.74 ( – 0.89 to – 0.58)

– 0.74 ( – 0.89 to – 0.60)

   7-joint score Backhaus²

– 0.90 ( -1.07 to – 0.74)

– 1.01 ( – 1.16 to – 0.87)

   6-joint score Perricone3

– 0.70 ( – 0.87 to – 0.52)

– 0.78 ( – 0.93 to – 0.62)

   Candidate set A score⁴

– 0.90 ( – 1.12 to – 0.68)

– 1.06 ( – 1.27 to – 0.87)

   Candidate set B score⁵

– 0.90 ( – 1.11 to – 0.69)

– 1.08 ( – 1.30 to – 0.88)

   Candidate set C score⁶

– 0.97 ( – 1.18 to – 0.77)

– 1.08 ( – 1.26 to – 0.92)

*SRM (standardised response mean) = mean change divided by the standard deviation of the change. CI = confidence interval; GSUS = grey-scale ultrasound; PDUS = power Doppler ultrasound. Patients in the early RA cohort with data on 3 months (n=113) and 6 months (n=109).

¹12-joint score Naredo et al: MCP2, MCP3, wrist, elbow, knee, ankle and TP tendon bilaterally (Naredo et al, Arthritis Rheum 2008).

²7-joint score Backhaus: MCP2, MCP3, PIP2, PIP3, wrist, MTP2, MTP5 and ECU tendon dominant side (Backhaus et al, Arthritis Rheum 2009). 

36-joint score Perricone: MCP2, wrist, knee bilaterally (Perricone et al, Rheumatology 2012).

⁴Candidate set A score: MCP1, MCP2, PIP3, radiocarpal, elbow, MTP1, MTP2, tibialis posterior (TP) tendon group and extensor carpi ulnaris (ECU) tendon bilaterally (Aga et al, Ann Rheum Dis 2015).

⁵Candidate set B score: same as candidate set A with addition of MCP5 and MTP5 (Aga et al, Ann Rheum Dis 2015).

⁶Candidate set C score: MCP1, MCP2, MCP3, PIP2, PIP3, radiocarpal, MTP2, MTP3 and ECU tendon bilaterally.

 

 

 

 

 


Disclosure: A. B. Aga, None; E. Lie, None; I. C. Olsen, None; H. B. Hammer, None; T. Uhlig, None; D. van der Heijde, None; T. K. Kvien, None; E. A. Haavardsholm, AbbVie, 2,Pfizer Inc, 2,MSD, 2,Roche Pharmaceuticals, 2,UCB, 2.

To cite this abstract in AMA style:

Aga AB, Lie E, Olsen IC, Hammer HB, Uhlig T, van der Heijde D, Kvien TK, Haavardsholm EA. Development of an Ultrasound Joint Inflammation Score for Rheumatoid Arthritis through a Data-Driven Approach [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/development-of-an-ultrasound-joint-inflammation-score-for-rheumatoid-arthritis-through-a-data-driven-approach/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-an-ultrasound-joint-inflammation-score-for-rheumatoid-arthritis-through-a-data-driven-approach/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology